Home > Cardiology > Early vasodilation in acute HF does not improve outcomes

Early vasodilation in acute HF does not improve outcomes


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ESC 2019
Trial
GALACTIC
Results from the GALACTIC trial showed that early intensive vasodilation does not improve 180-day all-cause mortality and rehospitalisation in patients hospitalised for acute heart failure (HF), despite the use of individualised doses of various agents. The GALACTIC trial hypothesised that early goal-directed therapy with maximal and persistent vasodilation would be able to achieve better clinical outcomes than standard care given to patients who were hospitalised for acute HF. A total of 781 patients were randomised to early goal-directed therapy or standard care until the moment of discharge. Early goal-directed therapy combined high and personalised doses of vasodilators including sublingual and transdermal nitrates, oral hydralazine for 48 hours to avoid tolerance to nitrates, and rapid up-titration of angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers. All other therapies including loop diuretic dose and duration, beta-blocke...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on